Abstract:Abstract Background: Anti-vascular endothelial growth factor (anti-VEGF) therapy improves disease-free but not overall survival in metastatic breast cancer. To seek further insight on resistance to anti-VEGF antibody bevacizumab (BEV) at the molecular level, we developed breast cancer xenograft models allowing comparison of tumor response at different time-points. Here we report the gene expression and miRNA analyses of response and non-response to BEV in these models. Methods: MCF-7 cells transfected with control vector (ML20) or VEGF (MV165) were implanted into the mammary fat pads of athymic mice. Tumors from short-term treatment with BEV (3 weeks; Responders to BEV, R) or long-term treatment (8 weeks; Non-Responders, NR) or with vehicle control group (V) were subjected to whole-genome gene expression analysis (Human WG-6v2 Expression Beadchips, Illumina) and miRNA profiling (TaqMan ArrayHuman MicroRNA A+B Cards Set v3.0, Applied Biosystems).Validation of the chosen genes was performed using quantitative real-time RT-PCR (qRT-PCR) and Immunohistochemistry (IHC). Results: Short-term treatment to BEV (3 weeks; 5 mg/kg, i.p./twice weekly) inhibited primary tumor growth significantly in MV165 xenografts compared with vehicle control, whereas BEV treatment did not affect the tumor growth in the ML20 model. MV165 xenografts progressed after 8 weeks of BEV treatment. Gene set enrichment analysis (GSEA) revealed that luminal A-related gene sets were enriched in MV165-R compared to MV165-NR group including DESMEDT (ESR1), SMID_Breast_Cancer_Luminal_A_up, and MASSARWEH_ Tamoxifen_Resistance_ Down. Myoepithelial-specific gene sets were upregulated in both the R and NR groups compared with the vehicle group. qRT-PCR analysis showed that estrogen receptor alpha (ESR1) representative for luminal A decreased significantly in the MV-165-NR group (P=0.001) compared to vehicle. In contrast, Cytokeratin 5 (KRT5) levels increased significantly in both R (P=0.02) and NR (P=0.03) groups. In addition, KRT14 was upregulated in R (P= 0.04) and in NR (P=0.14) group in comparison with the vehicle group, suggesting the upregulation of myoepithelial phenotype specific to BEV treated MV165 model, but not ML20 model. Similar results were obtained by IHC. Consistent with mRNA changes, ESR1 regulated miRNA such as miR-107 (P=0.007) and miRNA important in tamoxifen resistance such as mir-451 (P= 0.0003) were also altered in MV165-NR group compared to vehicle. Conclusion: These results suggest that treatment with BEV may alter the intrinsic subtypes in the presence of VEGF expression. These data may help to explain the variable results to anti-VEGF therapy based on the duration of BEV treatment. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-04-02.

Bevacizumab Promotes Active Biological Behaviors Of Human Umbilical Vein Endothelial Cells By Activating Tgf Beta 1 Pathways Via Off-Vegf Signaling

Effect of bevacizumab on the tight junction proteins of vascular endothelial cells.

Small extracellular vesicle-bound vascular endothelial growth factor secreted by carcinoma-associated fibroblasts promotes angiogenesis in a bevacizumab-resistant manner

Bevacizumab potentiates chemotherapeutic effect on T-leukemia/lymphoma cells by direct action on tumor endothelial cells.

Bevacizumab promotes venous thromboembolism through the induction of PAI-1 in a mouse xenograft model of human lung carcinoma

Inhibition of Angiogenesis and Extracellular Matrix Remodeling: Synergistic Effect of Renin-Angiotensin System Inhibitors and Bevacizumab

Synergistic Effects Of Bevacizumab In Combination With Beta-Elemene On Subcutaneous Xenografts Derived From Hct-116 Human Colon Cancer Cells

P3-04-02: Bevacizumab Treatment Alters Intrinsic Subtypes in a VEGF-Reinforced Xenograft Model of ER-Positive Breast Cancer.

Effect of bevacizumab on angiogenesis and related cytokines in mice with malignant pleural effusion

Experimental Study of Apoptosis in Leukemic Cell Lines Induced by Combined Use of Bevacizumab and Chemotherapeutic Drug

Tumor-derived Endothelial-Specific Molecule 1 Elicits Productive Angiogenesis and Tumor Metastasis to Promote Bevacizumab Resistance

The Effect of Anti-Vegf Drugs (bevacizumab and Aflibercept) on the Survival of Patients with Metastatic Colorectal Cancer (Mcrc)

Expression of Angiogenic Growth Factors VEGF, Bfgf and ANG1 in Colon Cancer after Bevacizumab Treatment in Vitro: A Potential Self-Regulating Mechanism.

Anti-vascular Endothelial Growth Factor Treatment Induces Blood Flow Recovery Through Vascular Remodeling in High-Fat Diet Induced Diabetic Mice.

Endothelial-Specific Molecule 1 Inhibition Lessens Productive Angiogenesis and Tumor Metastasis to Overcome Bevacizumab Resistance

Impacts of Bevacizumab on vascular endothelial growth factor and Sp1 expression in gastric cancer xenografts

Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab

Bevacizumab Regulates Cancer Cell Migration by Activation of STAT3.

Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy.

β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma

Metformin Alleviates Bevacizumab-Induced Vascular Endothelial Injury in Mice Through Growth Differentiation Factor 15 Upregulation.